Peripheral T Cell Lymphoma Clinical Trials

43 recruitingLast updated: May 5, 2026

There are 46 actively recruiting peripheral t cell lymphoma clinical trials across 18 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Tianjin, Tianjin Municipality, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Peripheral T Cell Lymphoma Trials at a Glance

46 actively recruiting trials for peripheral t cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 25 trials, with the heaviest enrollment activity in Shanghai, Tianjin, and Houston. Lead sponsors running peripheral t cell lymphoma studies include Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University, and Institute of Hematology & Blood Diseases Hospital, China.

Browse peripheral t cell lymphoma trials by phase

Treatments under study

About Peripheral T Cell Lymphoma Clinical Trials

Looking for clinical trials for Peripheral T Cell Lymphoma? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Peripheral T Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Peripheral T Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Phase 2

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T Cell Lymphoma
The First Affiliated Hospital of Soochow University31 enrolled1 locationNCT05182957
Recruiting
Phase 2

Study of Lacutamab in Peripheral T-cell Lymphoma

Relapse/RecurrencePeripheral T Cell Lymphoma
The Lymphoma Academic Research Organisation56 enrolled64 locationsNCT04984837
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin LymphomaNon-Hodgkin LymphomaPeripheral T Cell Lymphoma+4 more
Baylor College of Medicine90 enrolled2 locationsNCT06176690
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma
Fudan University51 enrolled1 locationNCT04512534
Recruiting

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Peripheral T Cell Lymphoma
Fudan University3,000 enrolled1 locationNCT07270861
Recruiting
Phase 2

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University25 enrolled1 locationNCT06519526
Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine58 enrolled1 locationNCT07470996
Recruiting
Phase 3

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine68 enrolled1 locationNCT07414758
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 2

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Peripheral T Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT06630091
Recruiting
Phase 2Phase 3

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine40 enrolled1 locationNCT07389616
Recruiting
Phase 1Phase 2

Evaluate the Safety and Clinical Activity of HH2853

Advanced Solid TumorPeripheral T Cell LymphomaFL Lymphoma+1 more
Haihe Biopharma Co., Ltd.254 enrolled25 locationsNCT04390737
Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine160 enrolled1 locationNCT07353840
Recruiting
Phase 3

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.120 enrolled1 locationNCT06776952
Recruiting
Phase 1Phase 2

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma
Sun Yat-sen University101 enrolled1 locationNCT07093710
Recruiting

Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine88 enrolled1 locationNCT07253129